Tafinlar 75 mg Capsule is a cutting-edge oral oncology medication containing Dabrafenib, a selective BRAF kinase inhibitor, developed to treat patients with specific types of cancer, including melanoma and non-small cell lung cancer (NSCLC), harboring the BRAF V600 mutation. Manufactured by Novartis, Tafinlar has revolutionized cancer therapy by targeting the molecular pathways responsible for tumor growth, offering patients a more personalized and effective treatment approach.
Key Product Information:
- Active Ingredient: Dabrafenib 75 mg
- Form: Oral Capsule
- Administration: Oral use
- Packaging: 120 capsules per box
- Manufacturer: Novartis Pharmaceuticals
Benefits of Tafinlar 75 mg (Dabrafenib):
- Targeted Cancer Therapy: Specifically inhibits the mutant BRAF V600 protein, which is a known driver of cancer growth in melanoma and NSCLC patients.
- Improves Progression-Free Survival: Clinical trials have shown that Tafinlar, especially when combined with MEK inhibitors like Trametinib, significantly extends progression-free survival in patients with BRAF-mutated cancers.
- Reduces Tumor Growth: Helps in slowing or stopping the growth of tumors in patients with BRAF V600 mutation-positive cancers.
- Combination Treatment Potential: Frequently prescribed alongside Trametinib (Mekinist) for enhanced anti-tumor effects and reduced resistance development.
- Oral Convenience: Capsule form allows easy administration at home, enhancing patient compliance.
Indications for Use:
- Unresectable or Metastatic Melanoma: For adult patients with BRAF V600E mutation.
- Non-Small Cell Lung Cancer (NSCLC): As part of combination therapy for BRAF V600E mutation-positive cases.
- Anaplastic Thyroid Cancer (ATC): In combination with Trametinib for BRAF V600 mutation-positive cases where no alternative treatment options are available.
How Does Tafinlar Work?
Tafinlar (Dabrafenib) works by inhibiting the abnormal BRAF V600 protein, a mutant enzyme that drives uncontrolled cell division and tumor growth. By blocking this pathway, Tafinlar disrupts cancer cell proliferation, inducing apoptosis (cell death) and slowing disease progression.
Dosage and Administration:
- Recommended Dose: 150 mg daily (2 capsules of 75 mg), taken twice daily, approximately 12 hours apart.
- Combination Therapy: Often paired with Trametinib for optimal results in BRAF-mutant cancers.
- Fasting Requirement: Take at least 1 hour before or 2 hours after a meal.
Safety & Side Effects:
- Common Side Effects: Fever, fatigue, nausea, headache, skin rash, joint pain.
- Serious Risks: Pyrexia, new primary malignancies, cutaneous squamous cell carcinoma, hyperglycemia, and liver function abnormalities.
- Monitoring: Regular blood tests and dermatologic evaluations are recommended.
Storage Instructions:
- Temperature: Store below 30°C (86°F).
- Keep Away From Moisture: Store in a dry place, in the original packaging.
Why Choose Tafinlar 75 mg Capsule?
Tafinlar 75 mg Capsule is part of a modern oncology breakthrough that allows for precision medicine tailored to genetic mutations driving cancer growth. When combined with Trametinib, Tafinlar has become the gold standard for managing advanced-stage BRAF V600 mutation-positive cancers, offering improved patient outcomes and quality of life.
Buy Tafinlar 75 mg Capsules Online:
Looking to buy Tafinlar 75 mg Dabrafenib Capsules online? We provide genuine, pharmacy-grade oncology medications from Novartis, ensuring quality and reliability. Order Tafinlar now and access cutting-edge targeted cancer therapy to support your treatment journey.
Değerlendirmeler
Henüz değerlendirme yapılmadı.